Danish medtech Coloplast has agreed to acquire voice box maker Atos Medical for 2.15 billion euros, or about $2.49 billion.
That deal represents a healthy return for Atos’ private equity owner, Paris-based PAI Partners, which bought the Swedish company back in 2016 for about 850 million euros. Coloplast describes Atos as an international market leader in the field of laryngectomy and a potential route to a new chronic care business.
Founded in 1986, Atos has been producing prosthetic voice boxes for over 30 years, designed for patients who have had their larynx surgically removed due to cancer or other conditions.
The company introduced an updated version of its Provox device in 2014, which helped users to speak hands-free. Since then, it has launched a smartphone app for voice rehabilitation exercises as well as devices designed for pediatric cases.
After the closure of the deal, which is slated for early 2022, Coloplast plans to run Atos as a separate strategic unit and brand; however, the company will operate on a shared business infrastructure that also supports Coloplast’s offerings in urology, continence and wound care, according to a statement.
Atos recently completed an acquisition of its own—nabbing three companies in one—to diversify into products for patients who have received a tube placed in their windpipe.
A deal was finalized last month for the German tracheostomy group TRACOE medical, which also oversees the Netherlands-based airway management developer MC Europe, and Kapitex, a U.K. manufacturer and distributor of medical devices for people with trouble swallowing.
“I am convinced that combining our companies will strengthen our ability to fast track the journey towards becoming a full range global player in the tracheostomy segment through a combined hospital and direct-to-consumer model and with a strong production footprint in Sweden and Germany,” Atos CEO Britt Meelby Jensen said in a statement when the deals closed Oct. 1.
The sale to Coloplast follows a report from Reuters this past summer that Atos Medical was gearing up to go public, potentially aiming for a 2 billion euro valuation.
“It has been very rewarding to be able to support Atos Medical’s growth in the last few years, with the company more than doubling in size and transforming into a true direct-to-consumer medtech company,” said Andreas Kumeth, partner at PAI. “We are also proud to have played a role in helping Atos Medical establish further specialities and become a more diversified ENT specialist.”
by Conor Hale
Source: fiercebiotech.com
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
